REVIEW ARTICLES
Etiology and response to drug treatment in heart failure
Ferenc Follath, MD, FESC*,
John G. F. Cleland, MD, FRCP, FESC, FACC ,
Werner Klein, MD, FESC and
Richard Murphy, PhD, BPharm
* University Hospital, Zürich, Switzerland
University of Glasgow, Glasgow, Scotland, United Kingdom
Medizinische Universitätsklinik, Graz, Austria
CBC Oxford, Oxford, United Kingdom
Manuscript received November 14, 1997;
revised manuscript received May 5, 1998,
accepted July 17, 1998.
Address for correspondence: Professor Ferenc Follath, Department of Internal Medicine, University Hospital, Zürich, Switzerland
Clinical trials in heart failure (HF) tend to randomize patients according to demographic characteristics and severity of left ventricular dysfunction, without taking account of the precise diagnosis. This article reviews results from recent trials suggesting that the etiology of HF, and particularly whether it is ischemic or nonischemic, may influence the long-term prognosis and the response to treatment. Some studies, but not all, suggest that nonischemic HF has a better prognosis than ischemic HF. The data on the benefits of angiotensin-converting enzyme inhibitors in ischemic versus nonischemic HF are conflicting. Carvedilol, and recently, bisoprolol have been shown to reduce mortality in ischemic and non-ischemic HF, whereas metoprolol has, to date, improved prognosis only in dilated cardiomyopathy. Better responses to digoxin, amlodipine and amiodarone have been reported in non-ischemic HF. There is at present no clear explanation for the apparent therapeutic differences between ischemic and nonischemic HF. Absence of a rigorous definition of "nonischemic HF" in many studies makes interpretation of the results difficult. Further studies to clarify the effects of etiology of HF on the response to treatment could be particularly important for preventing progression to more advanced stages, in which any type of drug therapy may have limited value in prolonging survival. An individualized therapeutic approach, based on etiology of HF and possibly other factors such as plasma drug levels or the levels of neurohormones, could result in major progress in treating HF patients.
This article has been cited by other articles:
|
|
|
|
 
D Yumino, H Wang, J S Floras, G E Newton, S Mak, P Ruttanaumpawan, J D Parker, and T D Bradley
Relationship between sleep apnoea and mortality in patients with ischaemic heart failure
Heart,
May 1, 2009;
95(10):
819 - 824.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kuner, A. S. Barth, M. Ruschhaupt, A. Buness, L. Zwermann, E. Kreuzer, G. Steinbeck, A. Poustka, H. Sultmann, and M. Nabauer
Genomic analysis reveals poor separation of human cardiomyopathies of ischemic and nonischemic etiologies
Physiol Genomics,
June 1, 2008;
34(1):
88 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Kim and H. Kang
Systolic Blood Pressure and Outcomes in Patients Hospitalized With Acute Heart Failure
JAMA,
February 28, 2007;
297(8):
807 - 808.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Horowitz and J. A. Kennedy
Time to Address the Cardiac Metabolic "Triple Whammy": Ischemic Heart Failure in Diabetic Patients
J. Am. Coll. Cardiol.,
December 5, 2006;
48(11):
2232 - 2234.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Senior, R. Janardhanan, P. Jeetley, and L. Burden
Myocardial Contrast Echocardiography for Distinguishing Ischemic From Nonischemic First-Onset Acute Heart Failure: Insights Into the Mechanism of Acute Heart Failure
Circulation,
September 13, 2005;
112(11):
1587 - 1593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yoshinari, H. Yaoita, K. Maehara, and Y. Maruyama
Different therapeutic responses to treadmill exercise of heart failure due to ischemia and infarction in rats
Cardiovasc Res,
February 1, 2005;
65(2):
457 - 468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Kittleson, S. Q. Ye, R. A. Irizarry, K. M. Minhas, G. Edness, J. V. Conte, G. Parmigiani, L. W. Miller, Y. Chen, J. L. Hall, et al.
Identification of a Gene Expression Profile That Differentiates Between Ischemic and Nonischemic Cardiomyopathy
Circulation,
November 30, 2004;
110(22):
3444 - 3451.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M Shindler
Nonischaemic heart failure and diabetes mellitus
Eur. Heart J.,
April 2, 2004;
25(8):
629 - 630.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. de Groote, N. Lamblin, F. Mouquet, D. Plichon, E. McFadden, E. Van Belle, and C. Bauters
Impact of diabetes mellitus on long-term survival in patients with congestive heart failure
Eur. Heart J.,
April 2, 2004;
25(8):
656 - 662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Felker, R. L. Benza, A. B. Chandler, J. D. Leimberger, M. S. Cuffe, R. M. Califf, M. Gheorghiade, C. M. O'Connor, and OPTIME-CHF Investigators
Heart failure etiology and response tomilrinone in decompensated heart failure: Results from the OPTIME-CHF study
J. Am. Coll. Cardiol.,
March 19, 2003;
41(6):
997 - 1003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.A de Boer and D.J van Veldhuisen
Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs
Eur. Heart J. Suppl.,
April 1, 2002;
4(suppl_D):
D111 - D116.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. M. Felker, L. K. Shaw, and C. M. O'Connor
A standardized definition of ischemic cardiomyopathy for use in clinical research
J. Am. Coll. Cardiol.,
January 16, 2002;
39(2):
210 - 218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G F Cleland, J. John, J. Dhawan, and A. Clark
What is the optimal medical management of ischaemic heart failure?
Br. Med. Bull.,
October 1, 2001;
59(1):
135 - 158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Dries, N. K. Sweitzer, M. H. Drazner, L. W. Stevenson, and B. J. Gersh
Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction
J. Am. Coll. Cardiol.,
August 1, 2001;
38(2):
421 - 428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yaoita, A. Sakabe, K. Maehara, and Y. Maruyama
Different Effects of Carvedilol, Metoprolol, and Propranolol on Left Ventricular Remodeling After Coronary Stenosis or After Permanent Coronary Occlusion in Rats
Circulation,
February 26, 2002;
105(8):
975 - 980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
